Selective glucocorticoid receptor agonists for the treatment of inflammatory conditions. (360G-Wellcome-082979_Z_07_C)
Research by Professor David Ray and his team at University of Manchester has identified how to modulate the function of the glucocorticoid receptor.The glucocorticoid receptor responds to both natural hormones and synthetic glucocorticoids to inhibit the inflammatory response. Inflammation lies behind many important human diseases, including rheumatoid arthritis, and opening up novel approaches for therapy offers new hope for these chronic, disabling conditions. The award will allow development of new molecules capable of harnessing the glucocorticoid receptor for treatment of multiple inflammatory diseases, without the wide range of side effects that currently limit use of conventional drugs. If successful the research will lead to an orally active drug for use in inflammatory arthritis within five years.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 444497 |
| Applicant Surname | Ray |
| Approval Committee | Seeding Drug Discovery Committee |
| Award Date | 2010-02-22T00:00:00+00:00 |
| Financial Year | 2009/10 |
| Grant Programme: Title | Seeding Drug Discovery Award |
| Internal ID | 082979/Z/07/C |
| Lead Applicant | Prof David Ray |
| Partnership Value | 444497 |
| Planned Dates: End Date | 2011-09-29T00:00:00+00:00 |
| Planned Dates: Start Date | 2009-04-30T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | North West |